| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_11853964b5a94425431547dba6253b1f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-86 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-86 |
| filingDate |
2007-05-24^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2011-08-30^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08291ff72aca4f6208783bb5b884fed3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b9f48c388c85a375b202142f458fffc |
| publicationDate |
2011-08-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8008086-B2 |
| titleOfInvention |
Protocol for monitoring direct thrombin inhibition |
| abstract |
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of hemostasis therapies including anticoagulation therapies such as direct thrombin inhibition therapies. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3611507-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-202014002289-U1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2015171116-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10188302-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014144259-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013101836-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016019145-A1 |
| priorityDate |
1999-02-22^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |